<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118559</url>
  </required_header>
  <id_info>
    <org_study_id>150-CL-019</org_study_id>
    <nct_id>NCT01118559</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150</brief_title>
  <official_title>Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effect of food on the pharmacokinetics of YM150 in healthy male
      adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of food on the pharmacokinetics of YM150 in healthy non-elderly adult
      male subjects using a 2×2 crossover design. Also, to evaluate the safety of YM150.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of YM150 and its metabolites</measure>
    <time_frame>for 3 days after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by AEs, vital signs, 12-lead ECG and lab tests</measure>
    <time_frame>for 3 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT (prothrombin time)</measure>
    <time_frame>for 3 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aPTT (activated partial thromboplastin time)</measure>
    <time_frame>for 2 days after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXa (factor Xa) activity</measure>
    <time_frame>for 1 days after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <condition>Pharmacokinetics of YM150</condition>
  <arm_group>
    <arm_group_label>fast-fed sequence group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug is administered in a fasted condition first, and fed-condition study follows</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fed-fast sequence group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug is administered in a fed condition first, and fasted-condition study follows</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM150</intervention_name>
    <description>oral</description>
    <arm_group_label>fast-fed sequence group</arm_group_label>
    <arm_group_label>fed-fast sequence group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: ≥50.0 kg, &lt;80.0 kg

          -  BMI: ≥17.6, &lt;26.4

          -  Healthy, as judged by the investigator or sub-investigator based on the results of
             physical examinations and lab tests

        Exclusion Criteria:

          -  Received any investigational drugs within 120 days before the study

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or
             blood components within 14 days before the study

          -  Received medication within 7 days before the study

          -  A deviation from the assessment criteria of physical examinations or laboratory tests

          -  A deviation from the normal reference range of coagulation test [PT or aPTT]

          -  History of drug allergies

          -  Upper gastrointestinal disease within 7 days before the study

          -  Concurrent or previous hepatic, gastrointestinal, heart, cerebrovascular or
             respiratory diseases

          -  Concurrent or previous malignant tumor

          -  Previous treatment with YM150
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <last_update_submitted>May 5, 2010</last_update_submitted>
  <last_update_submitted_qc>May 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>YM150</keyword>
  <keyword>Food effect</keyword>
  <keyword>Healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darexaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

